Immunitybio Inc (IBRX) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Study Overview: ImmunityBio Inc. has completed a Phase 1b/2 clinical study titled ‘A Phase 1b/2 Study of HCW9218, a Bifunctional TGF-β Antagonist/IL-15 Protein Complex, for Advanced Pancreatic Cancer.’ The study aimed to evaluate the safety and efficacy of HCW9218 in treating patients with advanced pancreatic carcinoma, a condition with limited treatment options and poor prognosis.
Intervention/Treatment: The study tested HCW9218, an experimental drug designed as a bifunctional TGF-β antagonist/IL-15 protein complex. This drug aims to inhibit tumor growth and enhance immune response in patients with advanced pancreatic cancer.
Study Design: The study was interventional, employing a single-group assignment model without masking, meaning all participants received the experimental treatment. The primary purpose was treatment-focused, assessing the drug’s potential benefits in a real-world setting.
Study Timeline: The study began on March 11, 2022, and was completed with the last update submitted on November 21, 2025. These dates are crucial as they mark the progression from initiation to the latest update, indicating the study’s completion and readiness for result dissemination.
Market Implications: The completion of this study could positively influence ImmunityBio’s stock performance by showcasing its commitment to innovative cancer treatments. Successful outcomes may enhance investor confidence and position the company favorably against competitors in the oncology sector.
The study is completed, with further details available on the ClinicalTrials portal.
To learn more about IBRX’s potential, visit the Immunitybio Inc drug pipeline page.